Bain Capital Life Sciences Investors
Latest statistics and disclosures from Bain Capital Life Sciences Investors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are HTFL, NAMS, OLMA, SVRA, PHVS, and represent 77.80% of Bain Capital Life Sciences Investors's stock portfolio.
- Added to shares of these 4 stocks: OLMA (+$42M), XFOR (+$22M), CCCC (+$12M), XLO.
- Reduced shares in these 9 stocks: CDTX (-$289M), NAMS (-$120M), UPB (-$30M), DNTH (-$24M), TNGX (-$18M), PHVS (-$11M), KYTX, IPSC, NAMSW.
- Sold out of its positions in IPSC, CDTX.
- Bain Capital Life Sciences Investors was a net seller of stock by $-419M.
- Bain Capital Life Sciences Investors has $1.3B in assets under management (AUM), dropping by -13.34%.
- Central Index Key (CIK): 0001703031
Tip: Access up to 7 years of quarterly data
Positions held by Bain Capital Life Sciences Investors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors holds 19 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Heartflow Inc/Sh (HTFL) | 27.8 | $363M | 12M | 29.15 |
|
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 19.6 | $256M | -31% | 7.3M | 35.08 |
|
| Olema Pharmaceuticals (OLMA) | 16.3 | $213M | +24% | 8.5M | 25.00 |
|
| Savara (SVRA) | 8.1 | $106M | 18M | 6.03 |
|
|
| Pharvaris N V (PHVS) | 6.0 | $78M | -11% | 2.8M | 27.75 |
|
| Solid Biosciences Com New (SLDB) | 3.4 | $45M | 7.9M | 5.64 |
|
|
| Upstream Bio (UPB) | 2.8 | $36M | -45% | 1.3M | 27.15 |
|
| X4 Pharmaceuticals Com New (XFOR) | 2.4 | $32M | +226% | 8.0M | 4.00 |
|
| Dianthus Therapeutics (DNTH) | 2.3 | $31M | -43% | 744k | 41.21 |
|
| Kyverna Therapeutics (KYTX) | 2.2 | $29M | -7% | 3.1M | 9.40 |
|
| Annexon (ANNX) | 2.0 | $26M | 5.2M | 5.02 |
|
|
| Rapid Micro Biosystems Class A Com (RPID) | 1.9 | $25M | 8.4M | 2.90 |
|
|
| Cabaletta Bio (CABA) | 1.6 | $21M | 9.7M | 2.19 |
|
|
| C4 Therapeutics Com Stk (CCCC) | 1.0 | $14M | +545% | 7.2M | 1.91 |
|
| Mersana Therapeutics (MRSN) | 0.8 | $10M | 347k | 28.93 |
|
|
| Atea Pharmaceuticals (AVIR) | 0.7 | $8.9M | 2.5M | 3.57 |
|
|
| Tango Therapeutics (TNGX) | 0.4 | $5.8M | -75% | 654k | 8.86 |
|
| Xilio Therapeutics (XLO) | 0.4 | $4.7M | +61% | 7.4M | 0.64 |
|
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.2 | $2.3M | 100k | 23.00 |
|
Past Filings by Bain Capital Life Sciences Investors
SEC 13F filings are viewable for Bain Capital Life Sciences Investors going back to 2017
- Bain Capital Life Sciences Investors 2025 Q4 filed Feb. 17, 2026
- Bain Capital Life Sciences Investors 2025 Q3 filed Nov. 14, 2025
- Bain Capital Life Sciences Investors 2025 Q2 filed Aug. 14, 2025
- Bain Capital Life Sciences Investors 2025 Q1 filed May 15, 2025
- Bain Capital Life Sciences Investors 2024 Q4 filed Feb. 14, 2025
- Bain Capital Life Sciences Investors 2024 Q3 filed Nov. 14, 2024
- Bain Capital Life Sciences Investors 2024 Q2 filed Aug. 12, 2024
- Bain Capital Life Sciences Investors 2024 Q1 filed May 15, 2024
- Bain Capital Life Sciences Investors 2023 Q3 filed Nov. 14, 2023
- Bain Capital Life Sciences Investors 2023 Q2 filed Aug. 14, 2023
- Bain Capital Life Sciences Investors 2023 Q1 filed May 15, 2023
- Bain Capital Life Sciences Investors 2022 Q4 filed Feb. 14, 2023
- Bain Capital Life Sciences Investors 2022 Q3 filed Nov. 14, 2022
- Bain Capital Life Sciences Investors 2022 Q2 filed Aug. 15, 2022
- Bain Capital Life Sciences Investors 2022 Q1 filed May 16, 2022
- Bain Capital Life Sciences Investors 2021 Q4 filed Feb. 14, 2022